Why Supernus Pharmaceuticals Plunged 15% Today
In response to the company announcing mixed fourth-quarter results and issuing weak guidance, shares of Supernus Pharmaceuticals (NASDAQ: SUPN), a biopharma focused on diseases of the central nervous system, slumped 15% on Wednesday.
The headline numbers for the quarter were mixed:
Image source: Getty Images.
Source Fool.com
